Cargando…

Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant

There is a growing interest in using monoclonal antibodies (mAbs) in the early stages of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection to prevent disease progression. Little is known about the efficacy of mAbs against the delta variant of concern and its clinical presentatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Cicchitto, Gaetano, Cardillo, Lorena, de Martinis, Claudio, Sabatini, Paola, Marchitiello, Rosita, Abate, Giovanna, Rovetti, Adele, Cavallera, Antonietta, Apuzzo, Camillo, Ferrigno, Francesco, Fusco, Giovanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950724/
https://www.ncbi.nlm.nih.gov/pubmed/35337057
http://dx.doi.org/10.3390/v14030650
_version_ 1784675211611734016
author Cicchitto, Gaetano
Cardillo, Lorena
de Martinis, Claudio
Sabatini, Paola
Marchitiello, Rosita
Abate, Giovanna
Rovetti, Adele
Cavallera, Antonietta
Apuzzo, Camillo
Ferrigno, Francesco
Fusco, Giovanna
author_facet Cicchitto, Gaetano
Cardillo, Lorena
de Martinis, Claudio
Sabatini, Paola
Marchitiello, Rosita
Abate, Giovanna
Rovetti, Adele
Cavallera, Antonietta
Apuzzo, Camillo
Ferrigno, Francesco
Fusco, Giovanna
author_sort Cicchitto, Gaetano
collection PubMed
description There is a growing interest in using monoclonal antibodies (mAbs) in the early stages of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection to prevent disease progression. Little is known about the efficacy of mAbs against the delta variant of concern and its clinical presentations. We evaluated the effect of casirivimab/imdevimab treatment among five delta vaccine breakthrough patients. Symptomatic non-hospitalized vaccinated patients were submitted to nasopharyngeal swabs for the detection of SARS-CoV-2 and Next-Generation Sequencing (NGS). Blood analysis and chest Computed Tomography were also performed. A cocktail of casirivimab/imdevimab was administrated, and patients were monitored weekly. Clinical evolution was evaluated by the regression of the symptoms, negative results by real-time RT-PCR, and by the need of hospitalization: these aspects were considered as significant outcomes. In four cases, symptom reversion and viral load reduction were observed within 2 days and 7 days after mAbs treatment, respectively. Only one case, suffering from thymoma, was hospitalized 2 days later because of respiratory failure, which reverted within 18 days. mAbs treatment seems to be safe and effective against the delta variant and its clinical manifestations.
format Online
Article
Text
id pubmed-8950724
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89507242022-03-26 Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant Cicchitto, Gaetano Cardillo, Lorena de Martinis, Claudio Sabatini, Paola Marchitiello, Rosita Abate, Giovanna Rovetti, Adele Cavallera, Antonietta Apuzzo, Camillo Ferrigno, Francesco Fusco, Giovanna Viruses Brief Report There is a growing interest in using monoclonal antibodies (mAbs) in the early stages of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection to prevent disease progression. Little is known about the efficacy of mAbs against the delta variant of concern and its clinical presentations. We evaluated the effect of casirivimab/imdevimab treatment among five delta vaccine breakthrough patients. Symptomatic non-hospitalized vaccinated patients were submitted to nasopharyngeal swabs for the detection of SARS-CoV-2 and Next-Generation Sequencing (NGS). Blood analysis and chest Computed Tomography were also performed. A cocktail of casirivimab/imdevimab was administrated, and patients were monitored weekly. Clinical evolution was evaluated by the regression of the symptoms, negative results by real-time RT-PCR, and by the need of hospitalization: these aspects were considered as significant outcomes. In four cases, symptom reversion and viral load reduction were observed within 2 days and 7 days after mAbs treatment, respectively. Only one case, suffering from thymoma, was hospitalized 2 days later because of respiratory failure, which reverted within 18 days. mAbs treatment seems to be safe and effective against the delta variant and its clinical manifestations. MDPI 2022-03-21 /pmc/articles/PMC8950724/ /pubmed/35337057 http://dx.doi.org/10.3390/v14030650 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Cicchitto, Gaetano
Cardillo, Lorena
de Martinis, Claudio
Sabatini, Paola
Marchitiello, Rosita
Abate, Giovanna
Rovetti, Adele
Cavallera, Antonietta
Apuzzo, Camillo
Ferrigno, Francesco
Fusco, Giovanna
Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant
title Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant
title_full Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant
title_fullStr Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant
title_full_unstemmed Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant
title_short Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant
title_sort effects of casirivimab/imdevimab monoclonal antibody treatment among vaccinated patients infected by sars-cov-2 delta variant
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950724/
https://www.ncbi.nlm.nih.gov/pubmed/35337057
http://dx.doi.org/10.3390/v14030650
work_keys_str_mv AT cicchittogaetano effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant
AT cardillolorena effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant
AT demartinisclaudio effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant
AT sabatinipaola effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant
AT marchitiellorosita effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant
AT abategiovanna effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant
AT rovettiadele effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant
AT cavalleraantonietta effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant
AT apuzzocamillo effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant
AT ferrignofrancesco effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant
AT fuscogiovanna effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant